Anaemia in Diabetes
Conditions
Interventions
Trade Name: Neorecormon
Product Name: Neorecormon
Product Code: N/A
Pharmaceutical Form: Injection*
INN or Proposed INN: Erythropoietin
Concentration unit: IU/l international unit(s)/litre
Concentrati
Sponsors
University Hospital Aintree NHS Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients must have diabetes mellitus Patients in active attendance at a designated care centre i.e. at least one visit in the last 6-12 months Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Patients aged <18years old Patients unwilling to participate in the study Patients with known cause of anaemia Patients with severe uncontrolled blood pressure Patients with evidence of cardiac decompensation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To determine the response of diabetic patients with anaemia of unknown origin to erythropoietin therapy;Secondary Objective: To determine the impact of anaemia and it's treatment on the patient's quality of life;Primary end point(s): Rise in Haemoglobin levels | — |
Countries
United Kingdom
Outcome results
None listed